About Laboratory Corp. of America (NYSE:LH)
Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD). The LCD segment is an independent clinical laboratory business, which offers menu of frequently requested and specialty testing through an integrated network of primary and specialty laboratories across the United States. The CDD segment offers drug development services, and provides a range of drug research and development (R&D) and market access services to biopharmaceutical companies and medical device companies across the world. It serves a range of customers, including managed care organizations (MCOs), biopharmaceutical companies, governmental agencies, physicians and other healthcare providers.
Industry, Sector and Symbol
Industry Healthcare Facilities & Services
Sub-IndustryHealth Care Services
Trailing P/E Ratio24.3902097902098
Forward P/E Ratio18.30
Sales & Book Value
Annual Sales$9.64 billion
Price / Sales1.84
Cash Flow$13.81 per share
Price / Cash12.63
Book Value$53.45 per share
Price / Book3.26
Net Income$732.10 million
Return on Equity16.75%
Return on Assets6.43%
Laboratory Corp. of America (NYSE:LH) Frequently Asked Questions
What is Laboratory Corp. of America's stock symbol?
Laboratory Corp. of America trades on the New York Stock Exchange (NYSE) under the ticker symbol "LH."
How were Laboratory Corp. of America's earnings last quarter?
Laboratory Corp. of America Holdings (NYSE:LH) released its quarterly earnings data on Wednesday, October, 25th. The medical research company reported $2.46 earnings per share for the quarter, topping the Zacks' consensus estimate of $2.38 by $0.08. The medical research company had revenue of $2.60 billion for the quarter, compared to analysts' expectations of $2.55 billion. Laboratory Corp. of America had a net margin of 7.40% and a return on equity of 16.75%. The company's revenue for the quarter was up 9.5% compared to the same quarter last year. During the same quarter last year, the company earned $2.25 EPS. View Laboratory Corp. of America's Earnings History.
When will Laboratory Corp. of America make its next earnings announcement?
Where is Laboratory Corp. of America's stock going? Where will Laboratory Corp. of America's stock price be in 2018?
13 brokerages have issued 12-month target prices for Laboratory Corp. of America's stock. Their forecasts range from $146.00 to $195.00. On average, they expect Laboratory Corp. of America's share price to reach $171.83 in the next year. View Analyst Ratings for Laboratory Corp. of America.
What are Wall Street analysts saying about Laboratory Corp. of America stock?
Here are some recent quotes from research analysts about Laboratory Corp. of America stock:
- 1. According to Zacks Investment Research, "Over the past six months LabCorp has been trading above the broader industry. The company’s Diagnostics business continues to remain strong on improving price, mix, acquisition and favorable foreign exchange. Also after several quarters of dull show, Covance Drug Development reported strong growth on the back of the acquisition of Chiltern, strong organic growth and favorable foreign currency translation. An increased 2017 guidance boosts investors’ confidence indicating chances of this bullish trend to be maintained in the fourth quarter too. However, the current economic uncertainty including challenging volume environment for testing laboratories and utilization weaknesses are looming headwinds for LabCorp. Also, the company's revenue growth was constrained by the impact from multiple hurricanes during the last reported quarter." (1/10/2018)
- 2. Canaccord Genuity analysts commented, "LH bounced back from an underwhelming Q3 with a good Q4 that beat our/consensus estimates on the top and bottom lines. The 2017 guide is what we expected and we believe sets an appropriate bar for the company to execute against. LH spent a good portion of time on its call (in the Q&A) defending its strategic planning and responded to questions about its reported interest (Reuters) to acquire NC-based CRO Pharmaceutical Product Development (PPD) for ~$8 billion. While on one hand the deal would make sense to bolster its Covance business, our sense from investors is that most would prefer to see LH return more of its capital to shareholders in the form of share repurchases, which LH re-initiated in Q4. Regardless, we think the stock is cheap and it remains one of our five top picks for 2017 as we expect "mean-reverted" multiple expansion and another solid year of FCF (~$975M, or $9.43/sh.) and strong capital deployment. BUY. We raise our estimates and PT to $150 from $140." (2/17/2017)
- 3. Mizuho analysts commented, "We are raising our price target to $139 ($135 previously) post 4Q on betterthan-expected cash flow guidance. We are maintaining our 2017E and 2018E adjusted EPS estimates of $9.65 and $10.32, respectively. LH reported a good 4Q and initial 2017 guidance despite some noise. The company also noted a more conservative approach to its CRO metrics, which we view favorably." (2/17/2017)
Who are some of Laboratory Corp. of America's key competitors?
Some companies that are related to Laboratory Corp. of America include Fresenius Medical Care AG & Co. (FMS), HCA Healthcare (HCA), Davita (DVA), Quest Diagnostics (DGX), Universal Health Services (UHS), NMC Health (NMC), Encompass Health (EHC), MEDNAX (MD), Chemed (CHE), Acadia Healthcare (ACHC), Select Medical (SEM), Udg Healthcare (UDG), LifePoint Health (LPNT), Tenet Healthcare (THC), Diplomat Pharmacy (DPLO), HMS (HMSY), China Cord Blood (CO) and The Providence Service (PRSC).
Who are Laboratory Corp. of America's key executives?
Laboratory Corp. of America's management team includes the folowing people:
- David P. King, Chairman of the Board, President, Chief Executive Officer (Age 61)
- Glenn A. Eisenberg, Chief Financial Officer, Executive Vice President (Age 55)
- John D. Ratliff, Chief Executive Officer - Covance Drug Development (Age 57)
- Lisa J. Uthgenannt, Chief Human Resource Officer (Age 56)
- Edward T. Dodson, Senior Vice President, Chief Accounting Officer, Principal Accounting Officer (Age 63)
- Lance V. Berberian, Senior Vice President, Chief Information Officer (Age 54)
- F. Samuel Eberts III, Senior Vice President, Chief Compliance Officer, Secretary, Chief Legal Officer (Age 57)
- Robert E. Mittelstaedt Jr., Lead Independent Director (Age 73)
- Kerrii B. Anderson, Independent Director (Age 60)
- Jean-Luc Belingard, Independent Director (Age 68)
Who owns Laboratory Corp. of America stock?
Laboratory Corp. of America's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Schwab Charles Investment Management Inc. (0.36%), Bank of Montreal Can (0.32%), AMI Asset Management Corp (0.24%), Country Trust Bank (0.14%), Bartlett & Co. LLC (0.14%) and National Pension Service (0.11%). Company insiders that own Laboratory Corp. of America stock include David P King, Dwight Gary Gilliland, Edward T Dodson, F Samuel Eberts III, Glenn A Eisenberg, James T Jr Boyle, Jean-Luc Belingard, Lance Berberian, Lisa J Uthgenannt, R Sanders Williams and Robert E Mittelstaedt Jr. View Institutional Ownership Trends for Laboratory Corp. of America.
Who sold Laboratory Corp. of America stock? Who is selling Laboratory Corp. of America stock?
Laboratory Corp. of America's stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, AMI Asset Management Corp, Contravisory Investment Management Inc., Country Trust Bank, Exxonmobil Investment Management Inc. TX, Catawba Capital Management VA, National Investment Services Inc. WI and Country Club Trust Company n.a.. Company insiders that have sold Laboratory Corp. of America company stock in the last year include David P King, Dwight Gary Gilliland, F Samuel Eberts III, Glenn A Eisenberg, Jean-Luc Belingard, Lance Berberian, Lisa J Uthgenannt, R Sanders Williams and Robert E Mittelstaedt Jr. View Insider Buying and Selling for Laboratory Corp. of America.
Who bought Laboratory Corp. of America stock? Who is buying Laboratory Corp. of America stock?
Laboratory Corp. of America's stock was purchased by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc., Wasatch Advisors Inc., Franklin Street Advisors Inc. NC, State of Alaska Department of Revenue, Sheets Smith Wealth Management, Koshinski Asset Management Inc., National Pension Service and Sawyer & Company Inc. View Insider Buying and Selling for Laboratory Corp. of America.
How do I buy Laboratory Corp. of America stock?
Shares of Laboratory Corp. of America can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Laboratory Corp. of America's stock price today?
One share of Laboratory Corp. of America stock can currently be purchased for approximately $174.39.
How big of a company is Laboratory Corp. of America?
Laboratory Corp. of America has a market capitalization of $17.75 billion and generates $9.64 billion in revenue each year. The medical research company earns $732.10 million in net income (profit) each year or $7.15 on an earnings per share basis. Laboratory Corp. of America employs 52,000 workers across the globe.
How can I contact Laboratory Corp. of America?
Laboratory Corp. of America's mailing address is 358 S MAIN ST, BURLINGTON NC, 27215. The medical research company can be reached via phone at 336-229-1127 or via email at [email protected]
MarketBeat Community Rating for Laboratory Corp. of America (LH)MarketBeat's community ratings are surveys of what our community members think about Laboratory Corp. of America and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Laboratory Corp. of America (NYSE:LH) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.62||2.58||2.62||2.58|
|Ratings Breakdown: ||0 Sell Rating(s)|
5 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
5 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
5 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
5 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$171.83||$171.45||$170.33||$156.64|
|Price Target Upside: ||5.39% upside||9.89% upside||12.27% upside||1.92% upside|
Laboratory Corp. of America (NYSE:LH) Consensus Price Target History
Laboratory Corp. of America (NYSE:LH) Analyst Ratings History
(Data available from 1/21/2016 forward)
Laboratory Corp. of America (NYSE:LH) Earnings History and Estimates Chart
Laboratory Corp. of America (NYSE LH) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|10/25/2017||Q3 2017||$2.38||$2.46||$2.55 billion||$2.60 billion||View||N/A|
|7/26/2017||Q2 2017||$2.40||$2.47||$2.47 billion||$2.50 billion||View||N/A|
|4/25/2017||Q1 2017||$2.19||$2.22||$2.41 billion||$2.41 billion||View||N/A|
|2/16/2017||Q416||$2.13||$2.15||$2.35 billion||$2.39 billion||View||Listen|
|10/26/2016||Q316||$2.29||$2.25||$2.38 billion||$2.40 billion||View||Listen|
|7/27/2016||Q216||$2.30||$2.31||$2.33 billion||$2.40 billion||View||Listen|
|4/25/2016||Q116||$1.96||$2.02||$2.19 billion||$2.30 billion||View||Listen|
|2/18/2016||Q415||$1.99||$1.98||$2.22 billion||$2.24 billion||View||Listen|
|10/26/2015||Q315||$2.07||$2.07||$2.25 billion||$2.30 billion||View||Listen|
|7/28/2015||Q215||$2.03||$2.09||$2.22 billion||$2.20 billion||View||Listen|
|4/27/2015||Q115||$1.63||$1.73||$1.79 billion||$1.80 billion||View||Listen|
|2/20/2015||Q4||$1.63||$1.65||$1.49 billion||$1.51 billion||View||Listen|
|10/28/2014||Q3||$1.75||$1.80||$1.56 billion||$1.55 billion||View||Listen|
|7/18/2014||Q214||$1.77||$1.84||$1.50 billion||$1.52 billion||View||N/A|
|4/28/2014||Q114||$1.58||$1.51||$1.45 billion||$1.43 billion||View||Listen|
|2/7/2014||Q413||$1.66||$1.61||$1.46 billion||$1.44 billion||View||Listen|
|10/18/2013||Q313||$1.80||$1.80||$1.45 billion||$1.46 billion||View||Listen|
|7/19/2013||Q2 2013||$1.80||$1.80||$1.46 billion||$1.47 billion||View||Listen|
|4/19/2013||Q1 2013||$1.77||$1.74||$1.45 billion||$1.44 billion||View||Listen|
|2/8/2013||Q4 2012||$1.62||$1.54||$1.39 billion||$1.41 billion||View||Listen|
Laboratory Corp. of America (NYSE:LH) Earnings Estimates
2018 EPS Consensus Estimate: $10.35
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Laboratory Corp. of America (NYSE:LH)
No dividend announcements for this company have been tracked by MarketBeat.com
Laboratory Corp. of America (NYSE LH) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.90%
Institutional Ownership Percentage: 91.35%
Laboratory Corp. of America (NYSE LH) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|10/30/2017||Dwight Gary Gilliland||Director||Sell||971||$153.52||$149,067.92||3,501|| |
|9/6/2017||David P King||CEO||Sell||44,687||$156.86||$7,009,602.82||258,753|| |
|9/5/2017||David P. King||CEO||Sell||132,713||$157.06||$20,843,903.78|| |
|8/25/2017||F Samuel Eberts III||Insider||Sell||31,500||$155.22||$4,889,430.00||31,894|| |
|8/11/2017||R Sanders Williams||Director||Sell||3,100||$156.88||$486,328.00||10,073|| |
|8/1/2017||Glenn A Eisenberg||CFO||Sell||5,968||$159.46||$951,657.28||18,122|| |
|8/1/2017||Lisa J. Uthgenannt||Insider||Sell||5,000||$160.00||$800,000.00|| |
|5/22/2017||Lance Berberian||SVP||Sell||3,613||$139.84||$505,241.92||5,789|| |
|5/9/2017||Jean-Luc Belingard||Director||Sell||992||$142.19||$141,052.48||32,935|| |
|3/9/2017||Glenn A Eisenberg||CFO||Sell||2,300||$142.47||$327,681.00||12,556|| |
|2/24/2017||Robert E Mittelstaedt Jr||Director||Sell||5,300||$142.69||$756,257.00||18,208|| |
|8/9/2016||Lisa J Uthgenannt||Insider||Sell||1,177||$140.00||$164,780.00||3,660|| |
|8/4/2016||Glenn A Eisenberg||CFO||Sell||8,000||$140.10||$1,120,800.00||8,668|| |
|8/4/2016||Robert E Mittelstaedt Jr||Director||Sell||992||$140.15||$139,028.80||12,340|| |
|6/13/2016||David P King||CEO||Sell||196,400||$128.00||$25,139,200.00||271,210|| |
|4/27/2016||Edward T Dodson||Insider||Sell||9,392||$126.42||$1,187,336.64||2,717|| |
|3/31/2016||F Samuel Eberts III||Insider||Sell||4,219||$116.85||$492,990.15||24,751|| |
|3/31/2016||James T Jr. Boyle||CEO||Sell||18,132||$116.81||$2,117,998.92||58,191|| |
|3/14/2016||F Samuel Eberts III||Insider||Sell||309||$115.32||$35,633.88||18,529|| |
|3/14/2016||James T Jr. Boyle||CEO||Sell||1,543||$115.32||$177,938.76||26,410|| |
|2/25/2016||Jean-Luc Belingard||Director||Sell||1,296||$109.74||$142,223.04||30,722|| |
|2/16/2016||F Samuel Eberts III||Insider||Sell||370||$103.02||$38,117.40||18,066|| |
|2/16/2016||James T. Jr. Boyle||CEO||Sell||4,055||$103.02||$417,746.10||23,454|| |
|2/12/2016||F Samuel Eberts III||insider||Sell||405||$101.67||$41,176.35||18,436|| |
|2/12/2016||James T. Jr. Boyle||CEO||Sell||2,712||$101.67||$275,729.04||27,509|| |
|1/8/2016||F Samuel Eberts III||Insider||Sell||1,215||$119.05||$144,645.75||18,066|| |
|12/8/2015||F Samuel Eberts III||Insider||Sell||1,010||$123.31||$124,543.10||19,281|| |
|11/2/2015||R Sanders Williams||Director||Sell||1,850||$124.30||$229,955.00||4,176|| |
|7/1/2015||David P King||CEO||Sell||50,000||$121.78||$6,089,000.00|| |
|4/29/2015||Jean-Luc Belingard||Director||Sell||1,542||$123.10||$189,820.20|| |
|4/23/2015||James T Jr. Boyle||CEO||Sell||1,394||$126.56||$176,424.64|| |
|3/31/2015||Mark E Brecher||CMO||Sell||20,625||$126.98||$2,618,962.50|| |
|3/30/2015||Mark E Brecher||CMO||Sell||20,278||$126.98||$2,574,900.44|| |
|3/3/2015||James T Jr. Boyle||COO||Sell||1,237||$123.70||$153,016.90|| |
|2/13/2015||James T Jr. Boyle||COO||Sell||6,597||$116.68||$769,737.96|| |
|9/22/2014||David P King||CEO||Sell||65,234||$104.71||$6,830,652.14|| |
|9/5/2014||R Sanders Williams||Director||Sell||2,000||$107.95||$215,900.00|| |
|8/22/2014||David P King||CEO||Sell||65,233||$106.10||$6,921,221.30|| |
|7/22/2014||David P King||CEO||Sell||65,233||$105.55||$6,885,343.15|| |
|6/9/2014||James T Jr. Boyle||COO||Sell||38,600||$103.00||$3,975,800.00|| |
|5/7/2014||M Keith Weikel||Director||Sell||1,984||$98.28||$194,987.52||13,958|| |
|3/28/2014||James Jr. Boyle||COO||Sell||2,521||$98.36||$247,965.56||25,821|| |
|3/7/2014||William Hayes||CFO||Sell||23,848||$94.40||$2,251,251.20||19,400|| |
|2/13/2014||James Jr. Boyle||COO||Sell||4,123||$90.29||$372,265.67||28,188|| |
|2/11/2014||James Jr. Boyle||COO||Sell||1,204||$91.15||$109,744.60||28,188|| |
|1/27/2014||David King||CEO||Sell||24,200||$90.15||$2,181,630.00||63,699|| |
|12/24/2013||David King||CEO||Sell||25,000||$90.79||$2,269,750.00||63,628|| |
|10/24/2013||David P King||CEO||Sell||25,000||$100.91||$2,522,750.00|| |
|10/17/2013||James T Jr. Boyle||COO||Sell||24,400||$102.00||$2,488,800.00|| |
|9/25/2013||David King||CEO||Sell||25,000||$99.06||$2,476,500.00||63,628|| |
|8/26/2013||David King||CEO||Sell||25,000||$96.60||$2,415,000.00||63,628|| |
|8/21/2013||Robert Mittelstaedt, Jr.||Director||Sell||7,429||$96.86||$719,572.94||7,015|| |
|7/24/2013||David P King||CEO||Sell||25,000||$97.72||$2,443,000.00|| |
|6/24/2013||David P King||CEO||Sell||25,000||$98.66||$2,466,500.00|| |
|6/7/2013||James T Jr. Boyle||COO||Sell||63,100||$99.63||$6,286,653.00|| |
|5/28/2013||Mark E Brecher||Insider||Sell||16,900||$100.92||$1,705,548.00|| |
|5/21/2013||William B Hayes||CFO||Sell||127,200||$100.00||$12,720,000.00|| |
|5/17/2013||F Samuel Eberts III||Insider||Sell||10,000||$98.47||$984,700.00|| |
|5/10/2013||James T Jr. Boyle||COO||Sell||68,908||$93.82||$6,464,948.56|| |
|5/8/2013||Jean-Luc Belingard||Director||Sell||2,536||$92.88||$235,543.68|| |
|4/11/2013||William B Hayes||CFO||Sell||22,234||$95.00||$2,112,230.00|| |
Laboratory Corp. of America (NYSE LH) News Headlines
Laboratory Corp. of America (NYSE:LH) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Laboratory Corp. of America (NYSE:LH) Income Statement, Balance Sheet and Cash Flow Statement
Laboratory Corp. of America (NYSE LH) Stock Chart for Sunday, January, 21, 2018